Skip navigation
Skip navigation
You are using an outdated browser. Please upgrade your browser.

(22nd April 2003, Cambridge, UK) Leading provider of Drug Discovery Ontologies BioWisdom Ltd has appointed its Chief Scientific Officer, Dr Julie Barnes to its Board of Directors.

The appointment follows a successful completion of a round of equity financing, and reflects the need to align the company’s strategic activities with the needs of its pharmaceutical company customers. Barnes will use her 15 years experience of the pharmaceutical industry, as well as her recent experience in knowledge management, to assist in the strategic growth of the company.

"BioWisdom has established a lead position in the provision of very high quality and expertly annotated ontologies for the pharmaceutical industry, focussed on drug discovery. The key to BioWisdom’s success is to ensure that these ontologies are applied in ways that transform the way drug discovery scientists work," said Barnes. "I am very excited about having the opportunity to contribute to the growing business of BioWisdom at the board level."

"I am delighted to have the opportunity to work with Julie at both the executive and board level. Her experience of the industry has already proven a critical asset in growing our reputation with our customers," said Dr Gordon Smith Baxter, CEO of BioWisdom. “Julie’s strategic contribution to the board will be an additional benefit to the company"


About BioWisdom

BioWisdom Ltd., headquartered in Cambridge UK, established in September 2000, is a biomedical informatics company developing systems which help R&D professionals to access critical information and to assist them in the discovery and development of novel drug therapies. BioWisdom produces powerful life science ontologies, which describe important discovery concepts such as targets (e.g. genes and proteins) tissues and disease and the inter-relationships between them. BioWisdom's Discovery Ontologies deliver improved searching, integration and navigation through complex research information.

-ENDS-

For further information, please contact:

Gordon Smith Baxter, CEO
BioWisdom Ltd
Tel: +44 (0)1223 492100
email: gordon.baxter@biowisdom.com
http://www.biowisdom.com

This press release was distributed by ResponseSource Press Release Wire on behalf of BioWisdom Ltd in the following categories: Consumer Technology, Personal Finance, Business & Finance, Computing & Telecoms, for more information visit https://pressreleasewire.responsesource.com/about.